Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy

by Agata Mikolajczyk, Filip Mitula, Delfina Popiel, Bozena Kaminska, Maciej Wieczorek, Jerzy Pieczykolan
Published 2022-05-01

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells

by Anna M. Serwotka-Suszczak, Alicja M. Sochaj-Gregorczyk, Jerzy Pieczykolan, Daniel Krowarsch, Filip Jelen, Jacek Otlewski
Published 2017-02-01

Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. <em>Int. J. Mol. Sci.</em> 2017, <em>18</...

by Anna M. Serwotka-Suszczak, Alicja M. Sochaj-Gregorczyk, Jerzy Pieczykolan, Daniel Krowarsch, Filip Jelen, Jacek Otlewski
Published 2018-11-01

Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.

by Katarzyna Bazydlo-Guzenda, Pawel Buda, Mateusz Mach, Jerzy Pieczykolan, Izabela Kozlowska, Michal Janiszewski, Ewa Drzazga, Jakub Dominowski, Hubert Ziolkowski, Maciej Wieczorek, Shayne Cox Gad
Published 2021-01-01

Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma.

by Paweł Gunerka, Kamila Gala, Martyna Banach, Jakub Dominowski, Joanna Hucz-Kalitowska, Krzysztof Mulewski, Agnes Hajnal, Endre G Mikus, Damian Smuga, Marcin Zagozda, Krzysztof Dubiel, Jerzy Pieczykolan, Beata M Zygmunt, Maciej Wieczorek
Published 2020-01-01

A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects

by Mikolaj Matloka, Sylwia Janowska, Piotr Pankiewicz, Sofiya Kokhanovska, Tomasz Kos, Małgorzata Hołuj, Izabela Rutkowska-Wlodarczyk, Krzysztof Abramski, Monika Janicka, Piotr Jakubowski, Maciej Świątkiewicz, Marlena Welniak-Kaminska, Joanna Hucz-Kalitowska, Paulina Dera, Lukasz Bojarski, Paweł Grieb, Piotr Popik, Maciej Wieczorek, Jerzy Pieczykolan
Published 2022-11-01

Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists

by Piotr Pankiewicz, Marcin Szybiński, Katarzyna Kisielewska, Filip Gołębiowski, Patryk Krzemiński, Izabela Rutkowska-Włodarczyk, Rafał Moszczyński-Pętkowski, Lidia Gurba-Bryśkiewicz, Monika Delis, Krzysztof Mulewski, Damian Smuga, Jakub Dominowski, Artur Janusz, Michał Górka, Krzysztof Abramski, Agnieszka Napiórkowska, Marcin Nowotny, Krzysztof Dubiel, Katarzyna Kalita, Maciej Wieczorek, Jerzy Pieczykolan, Mikołaj Matłoka
Published 2021-07-01

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

by Delfina Popiel, Aleksandra Stańczak, Monika Skupińska, Agata Mikołajczyk, Paulina Stańczak, Filip Mituła, Joanna Hucz-Kalitowska, Kinga Jastrzębska, Damian Smuga, Jakub Dominowski, Monika Delis, Krzysztof Mulewski, Wojciech Pietruś, Daria Zdżalik-Bielecka, Karolina Dzwonek, Monika Lamparska-Przybysz, Abdellah Yamani, Patrycja Olejkowska, Natalia Piórkowska, Krzysztof Dubiel, Maciej Wieczorek, Maciej Wieczorek, Jerzy Pieczykolan
Published 2024-01-01

Design, Synthesis, and Development of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as a Novel Series of Selective PI3K<i>δ</i> Inhibitors: Part II—Benzimidazole Derivatives

by Mariola Stypik, Stanisław Michałek, Nina Orłowska, Marcin Zagozda, Maciej Dziachan, Martyna Banach, Paweł Turowski, Paweł Gunerka, Daria Zdżalik-Bielecka, Aleksandra Stańczak, Urszula Kędzierska, Krzysztof Mulewski, Damian Smuga, Wioleta Maruszak, Lidia Gurba-Bryśkiewicz, Arkadiusz Leniak, Wojciech Pietruś, Zbigniew Ochal, Mateusz Mach, Beata Zygmunt, Jerzy Pieczykolan, Krzysztof Dubiel, Maciej Wieczorek
Published 2022-07-01